In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Cytosorbents Corp (CTSO – Research Report), with a price target of $15. The company’s shares closed on Friday at $7.31, close to its 52-week low of $6.60.
“We maintain our Buy rating of CytoSorbents and our 12-month price target of $15.00 per share. We derive our price target based on the average of two valuation methods: 1) price-sales multiple using 7x 2025 sales estimate discounted at 12% and 2) price-earnings multiple using 25x 2025 earnings estimate discounted at 12%. 1) commercial; 2) partnership; 3) clinical; 4) financial; and 5) intellectual property.”
According to TipRanks.com, Ramakanth has 0 stars on 0-5 star ranking scale with an average return of -5.8% and a 30.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Collplant Holdings Ltd.
Currently, the analyst consensus on Cytosorbents Corp is a Strong Buy with an average price target of $16.50.
The company has a one-year high of $14.95 and a one-year low of $6.60. Currently, Cytosorbents Corp has an average volume of 201.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytoSorbents Corp. engages in the development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product, CytoSorb, is a extracorporeal cytokine filter and seeks to reduce cytokine storm that could otherwise cause massive inflammation, organ failure, and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.